Membrane technology

Global Industrial Wastewater Treatment Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 11, 2022
Environment, Research, Membrane, Adoption, Potential, Health, F&B, SWOT analysis, Oil, Mining, Address, Strategy, Solution, Government, Wastewater treatment, Efficiency, Food, Paper, Agriculture, Ultrafiltration, Traction, Risk, Membrane technology, SWOT, Maintenance, Greener, Growth, Sewage, Wastewater

The "Advancements in Membrane Technologies for Industrial Wastewater Treatment" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Advancements in Membrane Technologies for Industrial Wastewater Treatment" report has been added to ResearchAndMarkets.com's offering.
  • Membrane technologies are gaining traction in industrial wastewater treatment due to their higher efficiency in treating chemical oxygen demand, biological oxygen demand, total suspended substance, and organic compounds compared to conventional wastewater treatment.
  • Industrial wastewater treatment applications typically focus on two types of membrane technologies - membrane bioreactor and membrane distillation.
  • Interest from government agencies in promoting effective industrial wastewater treatment can boost the adoption potential of these technologies.

Global Reverse Osmosis Membrane Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, September 6, 2021
Technology, Other Technology, Separation processes, Chemistry, Physical sciences, Membrane technology, Water technology, Filters, Water treatment, Water desalination, Membrane, Reverse osmosis, Desalination, Semipermeable membrane

Reverse osmosis (RO) refers to a technology that deionizes or purifies water by pushing it through a semi-permeable membrane under high pressure.

Key Points: 
  • Reverse osmosis (RO) refers to a technology that deionizes or purifies water by pushing it through a semi-permeable membrane under high pressure.
  • The RO membrane is a thin layer of filtering material that separates contaminating agents and dissolved salts from drinking water.
  • What has been the impact of COVID-19 on the global reverse osmosis membrane market?
  • What is the structure of the global reverse osmosis membrane market and who are the key players?

National Kidney Foundation (NKF) and American Society of Nephrology (ASN) Statement on Patient Access to New Drug Treatment Options

Retrieved on: 
Wednesday, August 4, 2021
Medical specialties, Medicine, Clinical medicine, Kidney diseases, Organ failure, Nephrology, Membrane technology, Kidney failure, Kidney disease, Kidney, Dialysis, Kidney Research UK

Three entirely new classes of drugs now exist that can modify the progression of kidney disease.

Key Points: 
  • Three entirely new classes of drugs now exist that can modify the progression of kidney disease.
  • In simple terms, more interventions are available than ever before that can keep people with kidney disease alive and untethered to a dialysis machine.
  • Heart disease is the most common cause of death for people with kidney disease.
  • It is more common for people with kidney disease to die of heart disease than it is for them to progress to kidney failure.

Hydrogen and fuel cell catalyst maker Pajarito Powder receives Series-B investment from Hyundai Motor

Retrieved on: 
Wednesday, August 4, 2021
Hydrogen technologies, Energy, Articles, Hydrogen economy, Fuel cells, Proton, Membrane technology, Hyundai Motor Company, Hydrogen vehicle, Proton-exchange membrane

ALBUQUERQUE, N.M., Aug. 4, 2021 /PRNewswire/ -- U.S.-based startup Pajarito Powder has received a Series-B investment from Hyundai Motor Company.

Key Points: 
  • ALBUQUERQUE, N.M., Aug. 4, 2021 /PRNewswire/ -- U.S.-based startup Pajarito Powder has received a Series-B investment from Hyundai Motor Company.
  • The investment is intended to allow Hyundai Motor to expand its portfolio in the value chain of the hydrogen industry and strengthen the establishment of the hydrogen ecosystem.
  • Pajarito Powder manufacturers catalysts for use with proton-exchange membranes (PEM) and alkaline fuel cells and electrolyzers; it also manufactures a proprietary Precious-Metal-Free catalyst for fuel cells.
  • Pajarito Powder is a venture-backed startup funded by Hyundai Motor Company, Verge Fund, Omphalos Venture Partners and other private investors.

Sigyn Therapeutics Announces Successful Completion of Animal Pilot Study

Retrieved on: 
Thursday, July 29, 2021
Health sciences, Drug discovery, Academic disciplines, Life sciences, Membrane technology, Loki, Sigyn, Ásynjur, Pilot experiment, Therapy, Clinical trial, Dialysis

The pilot study represents the first-in-mammal use of Sigyn Therapy in a clinical setting.

Key Points: 
  • The pilot study represents the first-in-mammal use of Sigyn Therapy in a clinical setting.
  • In the pilot animal study, an adult version of Sigyn Therapywas administered to two porcine (pig) subjects (each ~ 40 kilos) to evaluate the feasibility of a therapeutic protocol designed to support subsequent clinical studies.In the study, Sigyn Therapy was deployed on a standard dialysis hardware system and utilized conventional blood-tubing set configurations.
  • Craig Roberts, Chief Technical Officer at Sigyn Therapeutics, added, We are pleased with the results of our pilot study, which provides us with clinical evidence that our device can be safely used without complications or adverse events.
  • This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.

Rockwell Medical, Inc. to Report Second Quarter 2021 Financial and Operating Results on August 16, 2021

Retrieved on: 
Thursday, July 29, 2021
Medicine, Clinical medicine, Membrane technology, Renal dialysis, Rockwell Medical, Hemodialysis, Dialysis, Nephrology, Artificial kidney

ET to discuss its financial results for the three months ended June 30, 2021, and recent operational highlights.

Key Points: 
  • ET to discuss its financial results for the three months ended June 30, 2021, and recent operational highlights.
  • A live webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, https://ir.rockwellmed.com/ .
  • The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform.
  • In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States.

$13.5 Billion Liquid Applied Membranes Global Market to 2026 - Featuring BASF, Dow Chemical and Sika Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021
Chemicals, Plastics, Manufacturing, Membrane technology, Water treatment, Water technology, Chemistry, Physical sciences, Natural sciences, Fouling, Membrane, Market

What are the inhibiting factors and impact of COVID-19 shaping the Global Liquid Applied Membranes Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Liquid Applied Membranes Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Liquid Applied Membranes Market?
  • What is the market share of the leading vendors in the Global Liquid Applied Membranes Market?
  • What modes and strategic moves are considered suitable for entering the Global Liquid Applied Membranes Market?

Alnylam Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

Retrieved on: 
Thursday, July 29, 2021
Research, FDA, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Medicine, Clinical medicine, Medical specialties, Membrane technology, Renal dialysis, Kidney diseases, Primary hyperoxaluria, Hyperoxaluria, Alnylam Pharmaceuticals, Hemodialysis, Lumasiran, Oxalate, Lumasiran, Primary Hyperoxaluria Type 1 (PH1), RNAi, Alnylam Pharmaceuticals, LUMASIRAN, PRIMARY HYPEROXALURIA TYPE 1 (PH1), RNAI, ALNYLAM PHARMACEUTICALS

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the ILLUMINATE-C Phase 3 open-label study of lumasiran in patients of all ages with advanced primary hyperoxaluria type 1 (PH1) associated with progressive decline in renal function.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the ILLUMINATE-C Phase 3 open-label study of lumasiran in patients of all ages with advanced primary hyperoxaluria type 1 (PH1) associated with progressive decline in renal function.
  • Results of the primary analysis at six months demonstrated substantial reduction in plasma oxalate from baseline in patients (N=21) with advanced disease, including those on hemodialysis.
  • Cohort A enrolled six patients with advanced PH1 who do not yet require dialysis, and Cohort B enrolled 15 patients who are hemodialysis-dependent.
  • Lumasiran also demonstrated positive results across key secondary endpoints, including measures of urinary oxalate (for patients in Cohort A) and additional measures of plasma oxalate.

Ardelyx Receives Complete Response Letter from U.S. FDA for New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

Retrieved on: 
Thursday, July 29, 2021
Chemistry, Physical sciences, Chemical elements, Detoxification, Dialysis, Membrane technology, Phosphorus, Calcium acetate/magnesium carbonate

To that end,the company intends to request a Type A meeting as soon as possible to discuss the CRL and determine potential paths forward for the approvalof tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis.

Key Points: 
  • To that end,the company intends to request a Type A meeting as soon as possible to discuss the CRL and determine potential paths forward for the approvalof tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis.
  • "We continue to believe tenapanor represents an important, first-in-class treatment option for patients with elevated phosphorus.
  • In our view, the serum phosphorus lowering data generated with tenapanor in all of our clinical studies is meaningful and clinically significant.
  • Ardelyx is developing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials.

Draper Develops Artificial Lung Technology with $4.9M U.S. Army Grant, Earns ASAIO Award

Retrieved on: 
Thursday, July 29, 2021
Medicine, Medical specialties, Medical terminology, Medical equipment, Membrane technology, Clinical medicine, Intensive care medicine, Extracorporeal membrane oxygenation, Artificial lung, Extracorporeal, Oxygen saturation

CAMBRIDGE, Mass., July 29, 2021 /PRNewswire-PRWeb/ --Artificial lung assist devices have been called life-savers for people who suffer respiratory failure.

Key Points: 
  • CAMBRIDGE, Mass., July 29, 2021 /PRNewswire-PRWeb/ --Artificial lung assist devices have been called life-savers for people who suffer respiratory failure.
  • Draper has done just that, making advances in an artificial lung technology called extracorporeal membrane oxygenation, or ECMO.
  • The device can become clogged with blood clots, which diminishes the membrane's ability to transfer oxygen and CO2.
  • We provide unbiased assessments of technology or systems designed or recommended by other organizationscustom designed, as well as commercial-off-the-shelf.